


## Patent Claims

1. Compounds of the formula I



in which

$R^1, R^2$  in each case independently of one another are aryl or Het, aryl is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, CN, A, OA or OH,

Het is a mono- or binuclear unsaturated heterocyclic ring system which is unsubstituted or mono-, di- or trisubstituted by Hal, A, CN, OA or OH and which contains one, two or three identical or different heteroatoms such as nitrogen, oxygen and sulfur,


A is alkyl having 1-6 C atoms,

Hal is F, Cl, Br or I,

and their physiologically acceptable salts and solvates.

2. Process for the preparation of compounds of the formula I according to Claim 1, characterized in that


a) a compound of the formula II



Sub  
A'

2000-09-01

in which L is Cl, Br, I or a free or reactively  
[sic] functionally modified OH group,  
and R<sup>1</sup> has the meaning indicated in Claim 1,  
is reacted with a compound of the formula III




III

in which R<sup>2</sup> and A have the meanings indicated in  
Claim 1,


10  
or

b) a compound of the formula IV



IV

in which R<sup>1</sup> and R<sup>2</sup> have the meanings indicated in  
Claim 1,  
is reacted with a compound of the formula V



V

in which R is iodine or bromine, X is Mg  
and A has the meaning indicated in Claim 1,  
in a Grignard reaction,

25  
or

30  
c) it is liberated from one of its functional  
derivatives by treating with a solvolysing or  
hydrogenolysing agent,

Sub  
A'  
comp  
20220-1506300

5

d) a base of the formula I which is obtained is converted into one of its salts, by treating with an acid.

10

3. Compounds of the formula I according to Claim 1, and their physiologically acceptable salts and solvates as medicaments.

15

4. ~~Compounds of the formula I according to Claim 1, and their physiologically acceptable salts and solvates as medicaments having 5-HT<sub>2A</sub> receptor-antagonistic action.~~

20✓

5. ~~Medicament according to Claim 4 for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia, anorexia nervosa, premenstrual syndrome and/or for positively affecting compulsive behaviour (obsessive-compulsive disorder, OCD).~~

25

30

6. ~~Pharmaceutical preparation, comprising at least one medicament according to Claim 5 and also, if appropriate vehicles and/or excipients and, if appropriate, other active compounds.~~

35

7. Use of compounds according to Claim 1 and/or of their physiologically acceptable salts and solvates for the production of a medicament having 5-HT<sub>2A</sub> receptor-antagonistic action.

8. Use according to Claim 7 for the production of a medicament for the treatment of psychoses, schizophrenia, depression, neurological disorders,

Sub  
A3

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
0	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

add  
A4